Monica B Pagano1, Suzy Morton2, Claudia S Cohn3, Sylvie Gross4, Jose Kutner5, Antoine Lewin6, Jeffrey McCullough3, Irwin Schweitzer7, Alan T Tinmouth8, Kamille West9, Simon J Stanworth10. 1. Laboratory Medicine, University of Washington Medical Center, Seattle, WA, USA. 2. NHS Blood and Transplant, University Hospitals Birmingham, Birmingham, UK. 3. Laboratory Medicine and Pathology, University of Minnesota Medical Center, Minneapolis, MN, USA. 4. Etablissement Français du Sang, La Plaine-Saint Denis, France. 5. Hemotherapy and Cell Therapy, Hospital Israelita Albert Einstein, Sao Paulo, Bazil. 6. Medical Affairs and Innovation, Héma-Québec, Montreal, QC, Canada. 7. Clinical Epidemiology Program Center for Transfusion Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 8. Departments of Medicine and Laboratory Medicine and Pathology, Ottawa Hospital Center for Transfusion Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 9. Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA. 10. NHS Blood & Transplant/Oxford University Hospitals NHS Foundation Trust, and University of Oxford; Oxford, UK.
Abstract
INTRODUCTION: Granulocyte transfusions are used to either treat or prevent life-threatening infections in neutropenic patients. Current evidence from clinical trials does not support or reject efficacy, nor guide practice. METHODS: A group of investigators have led the efforts to create an online registry to gather information on granulocyte transfusion practices from as broad a range of international settings. The data forms were adapted from an on-going study in England for electronic data management. Data is collected at the time of the request for granulocytes, weekly, at 28 days, and at 6 months. Information collected includes donor, granulocyte unit, patient and illness characteristics, and outcomes. RESULTS: The PROspective GRanulocyte usage and outcomEs Survey (ProGrES) is currently open for data entry. Centres across the UK have collected data on 80 subjects. Five institutions from 4 countries (2 from the US, 1 each from Brazil, and national services in Canada and France) are in the process of joining the study. Other countries have expressed interest. CONCLUSION: It is feasible to develop an international registry of granulocyte transfusions to characterise current practices and describe outcomes. This registry would provide a platform to explore the relationship between intervention and outcomes, and to generate evidence to inform granulocyte transfusion efficacy.
INTRODUCTION: Granulocyte transfusions are used to either treat or prevent life-threatening infections in neutropenic patients. Current evidence from clinical trials does not support or reject efficacy, nor guide practice. METHODS: A group of investigators have led the efforts to create an online registry to gather information on granulocyte transfusion practices from as broad a range of international settings. The data forms were adapted from an on-going study in England for electronic data management. Data is collected at the time of the request for granulocytes, weekly, at 28 days, and at 6 months. Information collected includes donor, granulocyte unit, patient and illness characteristics, and outcomes. RESULTS: The PROspective GRanulocyte usage and outcomEs Survey (ProGrES) is currently open for data entry. Centres across the UK have collected data on 80 subjects. Five institutions from 4 countries (2 from the US, 1 each from Brazil, and national services in Canada and France) are in the process of joining the study. Other countries have expressed interest. CONCLUSION: It is feasible to develop an international registry of granulocyte transfusions to characterise current practices and describe outcomes. This registry would provide a platform to explore the relationship between intervention and outcomes, and to generate evidence to inform granulocyte transfusion efficacy.
Authors: J Paul Kerr; Effie Liakopolou; Jessica Brown; Jacqueline M Cornish; David Fleming; Edwin Massey; Anthony Oakhill; Derwood H Pamphilon; Stephen P Robinson; April Totem; Alexandra M P I Valencia; David I Marks Journal: Br J Haematol Date: 2003-10 Impact factor: 6.998
Authors: Janusz Kaczorowski; Larry W Chambers; Tina Karwalajtys; Lisa Dolovich; Barbara Farrell; Beatrice McDonough; Rolf Sebaldt; Cheryl Levitt; William Hogg; Lehana Thabane; Karen Tu; Ron Goeree; J Michael Paterson; Mamdouh Shubair; Tracy Gierman; Shannon Sullivan; Megan Carter Journal: Prev Med Date: 2008-02-14 Impact factor: 4.018
Authors: R G Strauss; J P Hester; W R Vogler; D J Higby; A C Snikeris; K M Imig; C Greazel; G Mallard; D Burnett; S Gupta Journal: Transfusion Date: 1986 May-Jun Impact factor: 3.157
Authors: Edwin Massey; Kay Harding; Brennan C Kahan; Charlotte Llewelyn; Robert Wynn; John Moppett; Stephen P Robinson; Ann Green; Geoff Lucas; Deepak Sadani; Effie Liakopoulou; Paula Bolton-Maggs; David I Marks; Simon Stanworth Journal: Transfus Med Date: 2012-05-16 Impact factor: 2.019